Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and metabolic processes; dextrose supplies glucose for energy; electrolytes maintain fluid and electrolyte balance.
Aminosyn II 4.25% in Dextrose 20% provides amino acids for protein synthesis and dextrose as a caloric source. Amino acids are utilized for tissue repair and maintenance, while dextrose provides energy via glycolysis and oxidative phosphorylation.
Intravenous infusion: 500 mL/day initially, titrate to provide 1.5-2 g/kg/day of amino acids and 25-50 g/kg/day of dextrose; monitor electrolytes.
Intravenous infusion of 500 mL to 1 L per day. Typical rate: 1-2 mL/min (60-120 mL/hr). Adjust based on caloric and fluid requirements.
None Documented
None Documented
Amino acids: 0.5-2 hours (rapid clearance); dextrose: ~1-2 hours (insulin-dependent). Clinical context: Continuous IV infusion maintains steady state.
Not applicable; components are endogenous substances. Clinical effect (nitrogen balance) persists 4-6 hours post-infusion.
Renal (amino acids: ~80% reabsorbed, excess excreted unchanged; dextrose: primarily metabolized, small fraction excreted renally <5%; electrolytes: renal excretion proportional to intake and plasma levels).
Amino acids undergo metabolism; excess nitrogen is excreted renally as urea (80-90%), with minimal biliary/fecal elimination (<5%). Dextrose is metabolized.
Category C
Category C
Amino Acid Solution
Amino Acid Solution